Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency
characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor …

Optimizing end‐of‐life (EOL) care for multiple myeloma (MM) represents an unmet need. An
administrative cohort in Ontario, Canada was analysed between 2006 and 2018. Aggressive …

Background: Several factors are reported to be associated with palliative care utilization
among patients with various cancers, but literature is lacking on multiple myeloma (MM) …

Novel therapies for multiple myeloma (MM) have improved patient survival, but their high
costs strain healthcare budgets. End‐of‐life phases of treatment are generally the most …

Objective: Research has shown that palliative care improves the quality of life of cancer
patients; however, there is no literature on specific factors that predict its use in diffuse large …

Background Multiple myeloma is a hematologic malignancy characterized by its association
with a range of cardiovascular comorbidities, most notably heart failure. Our study aims to …

Background In spite of spectacular advances in the treatment of multiple myeloma, a
majority of patients will die from this disease or related complications. While a great amount …

Palliative and End-of-Life Care in Hematologic Malignancies: Progress and Opportunities. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …

Распространение коронавирусной инфекции COVID-19 привело к значительному
увеличению заболеваемости и смертности людей по всему миру. Пациенты с …